1 citations,
December 2021 in “JAAD case reports” A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.
48 citations,
April 2013 in “Expert Opinion on Investigational Drugs” Possible new treatments for common hair loss include drugs, stem cells, and improved transplants.
September 2017 in “Journal of Investigative Dermatology” The new scalp treatment preserves hair color, reduces hair loss, and maintains hair strength.
60 citations,
September 2015 in “Expert Review of Clinical Immunology” Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
1 citations,
January 2022 in “Faculty reviews” The best long-lasting results in treating hair loss may be achieved through combination therapy, including treatments like finasteride, minoxidil, and platelet-rich plasma injections.
53 citations,
February 2020 in “Expert Opinion on Pharmacotherapy” Finasteride and minoxidil work best together for hair loss.
1 citations,
August 2022 in “JAAD case reports” Pioglitazone use was linked to hair regrowth in a patient with permanent hair loss from cicatricial alopecia.
33 citations,
January 2016 in “Skin appendage disorders” The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.
39 citations,
November 2017 in “Journal of The American Academy of Dermatology” The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.
53 citations,
April 2018 in “Journal of The American Academy of Dermatology” Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.
22 citations,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.